Clorox Appoints New CEO, CFO, COO

Ticker: CLX · Form: 8-K · Filed: 2025-01-28T00:00:00.000Z

Sentiment: neutral

Topics: leadership-change, executive-appointment, management-transition

Related Tickers: CLX

TL;DR

Clorox gets a new CEO, Brenda Freeman, starting Feb 5th. Jacobsen is interim CFO, Novak interim COO.

AI Summary

On January 23, 2025, The Clorox Company announced changes in its executive leadership. The company appointed Brenda L. Freeman as Chief Executive Officer and a member of the Board of Directors, effective February 5, 2025. Additionally, Kevin M. Jacobsen was appointed Interim Chief Financial Officer, and Laura L. Novak was appointed Interim Chief Operating Officer.

Why It Matters

This filing signals a significant leadership transition at Clorox, with a new CEO taking the helm, which could lead to strategic shifts and impact the company's future performance.

Risk Assessment

Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty and signal strategic shifts, impacting investor confidence and operational execution.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Executive Officer of The Clorox Company?

Brenda L. Freeman has been appointed as the new Chief Executive Officer of The Clorox Company.

When is Brenda L. Freeman's appointment as CEO effective?

Brenda L. Freeman's appointment as CEO is effective February 5, 2025.

Who has been appointed as the Interim Chief Financial Officer?

Kevin M. Jacobsen has been appointed as the Interim Chief Financial Officer.

Who has been appointed as the Interim Chief Operating Officer?

Laura L. Novak has been appointed as the Interim Chief Operating Officer.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is January 23, 2025.

From the Filing

0001206774-25-000035.txt : 20250128 0001206774-25-000035.hdr.sgml : 20250128 20250128161558 ACCESSION NUMBER: 0001206774-25-000035 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250123 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250128 DATE AS OF CHANGE: 20250128 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLOROX CO /DE/ CENTRAL INDEX KEY: 0000021076 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 310595760 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-07151 FILM NUMBER: 25564385 BUSINESS ADDRESS: STREET 1: THE CLOROX COMPANY STREET 2: 1221 BROADWAY CITY: OAKLAND STATE: CA ZIP: 94612-1888 BUSINESS PHONE: 5102717000 MAIL ADDRESS: STREET 1: P.O. BOX 24305 CITY: OAKLAND STATE: CA ZIP: 94612-1305 8-K 1 clx4432551-8k.htm CURRENT REPORT false 0000021076 0000021076 2025-01-23 2025-01-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2025 THE CLOROX COMPANY (Exact name of registrant as specified in its charter) __________________ Delaware 1-07151 31-0595760 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation)   Identification No.) 1221 Broadway , Oakland , California 94612-1888 (Address of principal executive offices) (Zip code) ( 510 ) 271-7000 (Registrant's telephone number, including area code) Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock - $1.00 par value CLX New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company      ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐       Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On January 23, 2025, Kevin Jacobsen, Executive Vice President – Chief Financial Officer of The Clorox Company (the “Company”), provided notice of his intention to retire from the Company effective April 1, 2025, following nearly 30 years of service. Mr. Jacobsen will continue in an advisory capacity at the Company until June 2025. (c) On January 2

View on Read The Filing